Butyricicoccus pullicaecorum as Next Generation Probiotics
Background B. pullicaecorum and Diseases Services Products FAQs Resources
Introduction of B. pullicaecorum
Butyricicoccus pullicaecorum (B. pullicaecorum) has gained the status of a promising exponent of the recent wave of next-generation probiotics that are currently making their way into clinical practice. Creative Biolabs offers well-established and innovative One-Stop-Shop live biotherapeutic products (LBP) solutions. We are a multidisciplinary, qualified & experienced team.
Introduction of B. pullicaecorum
B. pullicaecorum cells are Gram-positive, anaerobic, non-motile, coccoid, and usually arranged in pairs. On M2GSC agar after 24 h at 42℃, colonies are white, smooth, circular and 1-2 mm in diameter. The G+C content of genomic DNA of the type strain is 54.5 mol%. The type strain, 25-3T (=LMG 24109T=CCUG 55265T), was isolated in 2007 from the caecal content of a 4-week-old broiler chicken. B. pullicaecorum was a butyrate-producing bacterium that may protect chickens from harmful microorganisms and necrotic enteritis. Whole-genome sequencing indicated B. pullicaecorum to be nonvirulent, with limited antibiotic resistance potential. B. pullicaecorum safety has been demonstrated in rats through both standard acute and 28-day repeated oral dose toxicity tests. Patients with infectious gastroenteritis, including inflammatory bowel disease, exhibit fewer B. pullicaecorum in their stools.
B. pullicaecorum and Disease
|
Diseases
|
Functions of B. pullicaecorum
|
|
Cancer
|
A safe butyrate-producing microbe, B. pullicaecorum, has been shown in clinical trials to possibly reduce cancer progression. Scientists demonstrated a correlation between urothelial cancer of the bladder and B. pullicaecorum. supplementation of B. pullicaecorum may provide opportunities for therapeutic intervention in different bladder cancers through the secretion of the specific SCFA, butyrate. Also, administration of B. pullicaecorum or its metabolites improved the clinical outcome of colorectal cancer (CRC) by activating the SCFA transporter and/or receptor, indicating that B. pullicaecorum was a probiotic with anti-CRC potential.
|
|
Inflammatory Bowel Disease (IBD)
|
B. pullicaecorum is a promising probiotic candidate and shows positive effects on chronic inflammations. The researchers evaluated the effect of B. pullicaecorum in a rat colitis model. Oral administration of B. pullicaecorum resulted in a significant protective effect, it was able to decrease lesion sizes and inflammation in a rat colitis model, and supernatant of B. pullicaecorum cultures prevents cytokine-induced epithelial integrity losses in an in vitro cell culture model.
|
Fig.1 Representative images of SCFA-related gene expression in mouse bladder after B. pullicaecorum administration.1
What Services Can We Provide for B. pullicaecorum at Creative Biolabs?
B. pullicaecorum Related Products at Creative Biolabs
We supply a variety of B. pullicaecorum strains of different preservation numbers. If you need other strains, please contact us.
-
Customized strain culture supernatant. (e.g.: for animal research)
-
Customized strain lyophilized powder containing certain CFU. (e.g.: for animal research)
B. pullicaecorum is a potential next-generation probiotic that is safe following oral administration. If you're researching on B. pullicaecorum, Creative Biolabs’ experienced staff aid with study design and strain analytical testing. Please feel free to contact us, let us know more about your needs.
FAQs
What are the main characteristics of B. pullicaecorum that make it a candidate for next-generation probiotics?
B. pullicaecorum is distinguished by its ability to produce butyrate, a short-chain fatty acid crucial for maintaining gut health. This strain is part of Clostridium cluster IV and is capable of positively influencing the gut microbiome by enhancing the production of butyrate in the colon, which plays a key role in anti-inflammatory processes and overall gut health.
Can B. pullicaecorum be used in animal health management?
Yes, research has demonstrated the utility of B. pullicaecorum in animal health, particularly in improving gut health and performance parameters such as body weight and feed conversion ratios in broiler chickens. It has been shown to contribute to resistance against enteric pathogens and enhance overall intestinal integrity.
What are the benefits of B. pullicaecorum over traditional probiotic strains?
Unlike traditional probiotics, B. pullicaecorum specifically targets the production of butyrate in the gut, which is less commonly addressed by conventional probiotic strains. This focus on butyrate production can offer more direct benefits in terms of anti-inflammatory effects and maintaining the health of the gut epithelium.
How does B. pullicaecorum influence the gut microbiome?
B. pullicaecorum enhances the gut microbiome's health by increasing butyrate levels, which can lead to improved barrier function, reduced inflammation, and better overall gut health. This action is particularly beneficial in counteracting disease-associated microbiota alterations.
What future research directions are suggested for B. pullicaecorum as a next-generation probiotic?
Future research is suggested to explore its efficacy in a broader range of health conditions and populations, including its potential impacts on chronic diseases influenced by gut health. Studies could also focus on optimizing dosage and formulation to enhance its stability and effectiveness in various gastrointestinal environments.
Resources
Reference
-
Wang, Y.C.; et al. Supplementation of Probiotic Butyricicoccus pullicaecorum Mediates Anticancer Effect on Bladder Urothelial Cells by Regulating Butyrate-Responsive Molecular Signatures. Diagnostics. 2021, 11(12): 2270.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
Related Services
